Page last updated: 2024-12-10

alpha-linolenic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280934
CHEMBL ID8739
CHEBI ID27432
CHEBI ID25048
SCHEMBL ID15282
MeSH IDM0027126

Synonyms (148)

Synonym
a-linolenic acid
BRD-K33396764-001-02-0
gtpl1049
alpha-la
c18:3
all-cis-9,15-octadecatrienoic acid
9,15-octadecatrienoic acid, (z,z,z)-
linolenic acid
nsc2042
.alpha.-linolenic acid
cis,cis-9,12,15-octadecatrienoic acid
nsc-2042
cis-delta(9,12,15)-octadecatrienoic acid
(z,z,z)-9,12,15-octadecatrienoic acid
9-cis,12-cis,15-cis-octadecatrienoic acid
all-cis-9,12,15-octadecatrienoic acid
cis,cis,cis-9,12,15-octadecatrienoic acid
(9z,12z,15z)-octadeca-9,12,15-trienoic acid
CHEBI:27432 ,
c18h30o2
alpha linolenic acid
IDI1_033846
BSPBIO_001376
9,12,15-octadecatrienoic acid, (9z,12z,15z)- (9ci)
cmc_7371
(9z,12z,15z)-9,12,15-octadecatrienoic acid
9,12,15-octadecatrienoic acid, (z,z,z)-
9,12,15-all-cis-octadecatrienoic acid
cis-delta9,12,15-octadecatrienoic acid
cis-9,cis-12,cis-15-octadecatrienoic acid
9,12,15-octadecatrienoic acid, (9z,12z,15z)-
linolenic acid (8ci)
(all-z)-9,12,15-octadecatrienoic acid
alpha-lnn
ai3-23986
ccris 656
(z,z,z)-octadeca-9,12,15-trienoic acid
NCGC00091058-01
nsc 2042
linolenic acid, crude
einecs 207-334-8
(9z,12z,15z)-octadecatrienoic acid
alpha-linolenic acid ,
C06427
9z,12z,15z-octadecatrienoic acid
linolenate
463-40-1
(9,12,15)-linolenic acid
linolenic acid, >=99%
NCGC00091058-04
DB00132
cis-9, cis-12, cis-15-octadecatrienoic acid
LMFA01030152
NCGC00091058-06
NCGC00091058-05
68424-45-3
NCGC00091058-07
NCGC00091058-02
MLS001336029
MLS001336030
smr000857336
linolenic acid, ~70% (gc)
MLS002454413
fa 18:3
HMS1989E18
octadecatrienoic acid, 9,12,15-(z,z,z)-
2DCD0473-E5CC-47BB-A0A4-95899AFF6C4B
bdbm50240347
cid_5280934
L000707
CHEMBL8739 ,
linolenic acid (18:3 n-3)
BML3-B05
HMS1361E18
HMS1791E18
L0050
NCGC00091058-09
NCGC00091058-10
NCGC00091058-08
unii-0rbv727h71
0rbv727h71 ,
dtxcid905506
cas-463-40-1
dtxsid7025506 ,
tox21_303322
NCGC00257192-01
(9z,12z,15z)octadeca-9,12,15-trienoic acid
tox21_201727
NCGC00259276-01
tox21_111071
HMS2233C13
AKOS016008598
linolenic acid [vandf]
vitamin f component alpha linolenic acid
linolenic acid (constituent of saw palmetto) [dsc]
linolenic acid [mart.]
fema no. 3380, linolenic acid-
18:3(n-3)
c18:3 (n-3)
linolenic acid [who-dd]
alpha-linolenic acid (c18:3 n3)
prifrac 2942
linolenic acid [inci]
linolenic acid [mi]
industrene 120
FA005
SCHEMBL15282
cis-9,12,15-octadecatrienoic acid
AC-33768
HMS3402E18
HMS3649H05
linolenic acid, analytical standard
alpha-linolenic acid, 1.0 mg/ml in ethanol, certified reference material
linolenic acid, vetec(tm) reagent grade, 98%
linolenic acid 10 microg/ml in methanol
alpha-linolenic acid; ala; cis-alpha-linolenic acid
all-cis-9,12,15-octadecatrienoate
(z,z,z)-9,12,15-octadecatrienoate
9,12,15-octadecatrienoate
9-cis,12-cis,15-cis-octadecatrienoate
cis-9,12,15-octadecatrienoate
a-linolenate
HY-N0728
cis,cis,cis-octadeca-9,12,15-trienoic acid
Q256502
SR-01000838327-2
sr-01000838327
alpha-linolenic-acid
9(z),12(z),15(z)-octadecatrienoic acid
CS-0009741
alpha -linolenic acid
octadeca-9z,12z,15z-trienoic acid
AS-57338
fa(18:3(9z,12z,15z))
alpha-linolenic acid tech.
29857-63-4
linolenic acid, tech grade
EN300-6734316
cis-delta-9,12,15-octadecatrienoic acid
linolensaeure
chebi:25048
linolenic acid (constituent of saw palmetto)
fatty acid cis, cis, cis 18:3 n-3
linolenic acid (constituent of evening primrose oil)
alpha-linolenic acid (c18:3) (constituent of krill oil)
linolenic acid (mart.)
alpha-linolenic acid (constituent of flax seed oil)
806 - fish oil supplement

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Toxic effects of oxygen were observed almost exclusively in those cells of yeast mutants deficient in superoxide dismutase, which contain linolenic acid in cellular lipids."( Superoxide dismutase deficiency and the toxicity of the products of autooxidation of polyunsaturated fatty acids in yeast.
Bajus, A; Biliński, T; Błaszczyński, M; Litwińska, J, 1989
)
0.28
"Methanol extracts of the hepatopancreas of mussels (Mytilus edulis) harvested at two locations (Ship Harbour and Wine Harbour) in eastern Nova Scotia, Canada, were found to be toxic to mice after intraperitoneal injection."( An incident of elevated levels of unsaturated free fatty acids in mussels from Nova Scotia and their toxic effect in mice after intraperitoneal injection.
Chadha, RK; Lawrence, JF; Ratnayake, WM; Truelove, JF, 1994
)
0.29
" Trilinolenin (18:3; omega-3) was toxic only after prolonged incubation."( Toxicity of polyunsaturated fatty acid esters for human monocyte-macrophages: the anomalous behaviour of cholesteryl linolenate.
Carpenter, KL; Hardwick, SJ; Hird, R; Law, NS; Marchant, CE; Mitchinson, MJ; Van Der Veen, C, 1997
)
0.3
" Both fats were well tolerated, and no adverse events or mortality were observed during the treatment nor after a 2-week observation period."( A 4-week repeated oral dose toxicity study of dairy fat naturally enriched in vaccenic, rumenic and α-linolenic acids in rats.
Anadon, A; Ares, I; de la Fuente, MA; Gomez-Cortes, P; Juarez, M; Martinez, MA; Martinez-Larranaga, MR; Ramos, E, 2011
)
0.37
" In conclusion, the "no observed adverse effect level" (NOAEL) of oral administration of PSO for 90 days in Beagle dogs was considered to be 3 g/kg/d."( Acute and sub-chronic 90-day oral toxicity study of Perilla seed oil in rodents and Beagle dogs.
Guan, J; Su, GY; Tian, YH; Zhang, HX; Zhao, YQ, 2019
)
0.51
" Toxicity studies showed PSO had great safety without any toxic and side effects, and could be processed to produce PSO microcapsule, microemulsion, nanoemulsion gel, biscuit, daily chemical products, soft capsule and other high value-added-products."( Could peony seeds oil become a high-quality edible vegetable oil? The nutritional and phytochemistry profiles, extraction, health benefits, safety and value-added-products.
Deng, R; Gao, J; Liu, P; Yi, J, 2022
)
0.72
" Although the main mechanism of the toxic effect of MTX is not known, it is stated that it causes oxidative stress and inflammation."( Alpha-linolenic acid protects against methotrexate-induced nephrotoxicity in mouse kidney cells.
Ates, T; Deger, M; Demir, E; Erdogan, KE; Kaplan, HM, 2023
)
2.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" This study determined whether the effect of FS, alone or in combination with TAM, is dose dependent, and it explored the potential mechanism of action."( Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
Chen, J; Cheng, A; Mann, J; Power, KA; Thompson, LU, 2007
)
0.34
"The current study aimed to evaluate the effect of fortified milk combined with a lifestyle and counselling programme on several CVD risk factors after a 3-month dietary intervention."( Additional benefit in CVD risk indices derived from the consumption of fortified milk when combined with a lifestyle intervention.
Antonopoulou, S; Grammatikaki, E; Kalogeropoulos, N; Manios, Y; Moschonis, G; Peristeraki, A; Petrogianni, M; Pitsavos, C, 2014
)
0.4
" The effects of 96 h treatment with ALA or DHA, at serum levels seen in mice (50-100 μM), alone and combined with TRAS (10 μg/ml), on BT-474 cell growth measured by trypan blue exclusion, apoptosis measured by flow cytometric analysis of Annexin-V/7-AAD stained cells (ALA and TRAS treatment only) and protein biomarkers HER2 signaling measured by western blot were determined."( α-linolenic acid and docosahexaenoic acid, alone and combined with trastuzumab, reduce HER2-overexpressing breast cancer cell growth but differentially regulate HER2 signaling pathways.
Kharotia, S; Klaire, S; Mason, JK; Thompson, LU; Wiggins, AK, 2015
)
0.42
" To test the hypothesis that an n-3 (ω-3) polyunsaturated fatty acid-rich food could synergize with other, largely polyphenol-rich foods by producing greater reductions in metabolic disease conditions, the intake of English walnuts was evaluated in combination with 9 other whole foods."( Consumption of Walnuts in Combination with Other Whole Foods Produces Physiologic, Metabolic, and Gene Expression Changes in Obese C57BL/6J High-Fat-Fed Male Mice.
Adamson, A; Hamilton-Reeves, J; Kinchen, JM; Luo, T; Miranda-Garcia, O; Shay, NF; Sullivan, DK, 2016
)
0.43
" The addition of a second whole food in combination with walnuts produced other changes in metabolite concentrations and gene expression patterns and other physiologic markers."( Consumption of Walnuts in Combination with Other Whole Foods Produces Physiologic, Metabolic, and Gene Expression Changes in Obese C57BL/6J High-Fat-Fed Male Mice.
Adamson, A; Hamilton-Reeves, J; Kinchen, JM; Luo, T; Miranda-Garcia, O; Shay, NF; Sullivan, DK, 2016
)
0.43

Bioavailability

Nanoliposome encapsulation combined with carboxymethyl chitosan (CMCS) surface decoration was employed to improve physicochemical stability and oral bioavailability of alpha-linolenic acid (ALA) Since isomerization reduces the bio availability of dietary fatty acids, the effect on the dopaminergic neurotransmission was studied.

ExcerptReferenceRelevance
" The kg was comparable to the apparent oral absorption rate constant estimated by the pharmacokinetic analysis of plasma concentration data."( Gastric emptying-limited oral absorption of alpha-linolenic acid administered as a milk fat-globule membrane (MFGM) emulsion in rats.
Ozeki, S; Sekiya, M; Watanabe, J; Yuasa, H, 1994
)
0.55
" Changes in plasma alpha-linolenic acid were equivalent when 12 g alpha-linolenic acid/d was provided as raw flaxseed flour (50 g/d) or flaxseed oil (20 g/d) suggesting high bioavailability of alpha-linolenic acid from ground flaxseed."( High alpha-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans.
Chen, ZY; Cunnane, SC; Ganguli, S; Hamadeh, MJ; Jenkins, DJ; Liede, AC; Menard, C; Wolever, TM, 1993
)
1.13
" Chylomicron triglyceride results show that the deuterated fatty acids were equally well absorbed and diet did not influence absorption."( Effect of dietary docosahexaenoic acid on desaturation and uptake in vivo of isotope-labeled oleic, linoleic, and linolenic acids by male subjects.
Adlof, RO; Duval, SM; Emken, EA; Nelson, GJ, 1999
)
0.3
"The aim of this study was to evaluate the potential of an emulsion incorporating unsaturated fatty acids to improve the mucosal absorption of poorly absorbed drugs from rat intestinal loops in situ, using a water-in-oil-in-water (W/O/W) multiple emulsion."( Enhanced enteral bioavailability of vancomycin using water-in-oil-in-water multiple emulsion incorporating highly purified unsaturated fatty acid.
Chiba, Y; Kajita, M; Morishita, M; Nagai, T; Takayama, K; Tokiwa, S, 2000
)
0.31
" The aim of this study was to test the hypothesis that low bioavailability of dietary 18:3n-3 to be converted to 22:6n-3 could partly explain this difference in fatty acid accretion."( Comparative bioavailability of dietary alpha-linolenic and docosahexaenoic acids in the growing rat.
Alessandri, JM; Durand, G; Guesnet, P; Houlier, F; Langelier, B; Latge, C; Poumès-Ballihaut, C, 2001
)
0.31
" To assess the effect of Entrox coating on the short-term bioavailability of ALA administered in the form of ALA-rich Perilla seed oil, 12 healthy subjects (6 males and 6 females) received in a random order Entrox-coated and non-coated ALA formulations, each as a single 6g dose separated by a 3-week washout period."( Bioavailability of omega-3 essential fatty acids from perilla seed oil.
Deutsch, L; Dresser, GK; Khalil, W; Kurowska, EM; Vachon, D, 2003
)
0.32
" Since isomerization reduces the bioavailability of dietary fatty acids, the effect of the conversion of alpha-linolenic acid into trans alpha-linolenic acid on the dopaminergic neurotransmission was studied."( Modification of the dopaminergic neurotransmitters in striatum, frontal cortex and hippocampus of rats fed for 21 months with trans isomers of alpha-linolenic acid.
Acar, N; Chardigny, JM; Darbois, M; Pasquis, B; Sébédio, JL, 2003
)
0.73
" Therefore, the absorption rate was LnA > CLA > alpha-ESA = PA."( Conjugated linolenic acid is slowly absorbed in rat intestine, but quickly converted to conjugated linoleic acid.
Abe, R; Ikeda, I; Imamura, J; Iwata, T; Kawakami, Y; Koba, K; Miyazawa, T; Nakagawa, K; Tsuzuki, T, 2006
)
0.33
" However, further research on the bioavailability of these nutrients is needed to confirm the potential benefits of these plants."( Coping strategies and nutritional health in rural Niger: recommendations for consumption of wild plant foods in the Sahel.
Glew, RS; Vanderjagt, D,
)
0.13
" However, before extensive work can be undertaken in clinical populations to determine its efficacy, basic information on ALA bioavailability from flaxseed and the physiological effects of its ingestion need to be examined."( Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed.
Austria, JA; Chahine, MN; Dupasquier, CM; Edel, AL; Malcolmson, LJ; Pierce, GN; Richard, MN, 2008
)
0.67
"The purpose of this study, therefore, was to determine the bioavailability of ALA when the flaxseed was ingested in the form of whole seed, milled seed or as flaxseed oil."( Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed.
Austria, JA; Chahine, MN; Dupasquier, CM; Edel, AL; Malcolmson, LJ; Pierce, GN; Richard, MN, 2008
)
0.67
" UVB is well absorbed in proteins and DNA leading to products such as cyclobutane pyrimidine dimers."( Fatty acids and vitamins generate singlet oxygen under UVB irradiation.
Bäumler, W; Knak, A; Landthaler, M; Maisch, T; Regensburger, J, 2012
)
0.38
" This review focuses on the consequences of dietary restriction in IEM on the bioavailability of long-chain polyunsaturated fatty acids (LCPUFAs) and on the attempts to ameliorate these consequences."( Long-chain polyunsaturated fatty acids in inborn errors of metabolism.
Decsi, T; Fekete, K, 2010
)
0.36
" The bioavailability of encapsulated LSO as against native oil was monitored in rats by measuring the uptake in vitro using the intestinal everted sac model and in-vivo administration of microemulsions of LSO to rats for a period of 30 days."( Uptake of α-linolenic acid and its conversion to long chain omega-3 fatty acids in rats fed microemulsions of linseed oil.
Lokesh, BR; Sugasini, D, 2012
)
0.38
" At levels relevant with human nutrition, increasing dietary ALA and reducing LA intake were both beneficial in increasing n-3 LC-PUFA bioavailability in tissues."( Comparative effects of well-balanced diets enriched in α-linolenic or linoleic acids on LC-PUFA metabolism in rat tissues.
Blanchard, H; Boulier-Monthéan, N; Catheline, D; Legrand, P; Pédrono, F; Rioux, V, 2013
)
0.39
" The present systematic review sets out to collate information from intervention studies examining the bioavailability of alternative vegetarian long chain omega-3 (n-3) polyunsaturated fatty acids (LC3PUFA) sources."( Bioavailability and potential uses of vegetarian sources of omega-3 fatty acids: a review of the literature.
Brennan, C; Derbyshire, E; Lane, K; Li, W, 2014
)
0.4
" Therefore, LNA-LMCS2 with low cytotoxicity and high bioavailability might be a promising substitute for CS in clinical use, such as treating osteoarthritis, atherosclerosis, etc."( Enhancing the intestinal absorption of low molecular weight chondroitin sulfate by conjugation with α-linolenic acid and the transport mechanism of the conjugates.
Cao, R; Cheng, Y; Li, J; Li, P; Sheng, J; Wang, D; Wang, F; Xiao, Y; Zhang, Q; Zhang, X; Zhong, C, 2014
)
0.4
" This study provides a real-time empirical evidence on the influence of nano formulation in enhancing bioavailability and antioxidative properties of ESA."( Comparative real-time study of cellular uptake of a formulated conjugated linolenic acid rich nano and conventional macro emulsions and their bioactivity in ex vivo models for parenteral applications.
Chakraborty, R; Dhar, P; Mallick, SK; Mukherjee, S; Paul, D, 2015
)
0.42
"Formulating healthy food rich in omega 3 fatty acids requires prior knowledge of the parameters influencing their bioavailability and their metabolic fate."( Impact of various emulsifiers on ALA bioavailability and chylomicron synthesis through changes in gastrointestinal lipolysis.
Amara, S; Cansell, M; Carrière, F; Couëdelo, L; Fonseca, L; Lecomte, M; Meugnier, E; Michalski, MC; Monteil, J; Pineau, G; Vaysse, C, 2015
)
0.42
"Although there is extensive information describing the positive biological effects of conjugated linoleic acid and its main isomer rumenic acid (RA; C18:2 cis 9, trans 11), and alpha-linolenic acid (ALA) and vaccenic acid (TVA), data about their bioavailability are not available."( Oral Absorption and Disposition of alpha-Linolenic, Rumenic and Vaccenic Acids After Administration as a Naturally Enriched Goat Dairy Fat to Rats.
Anadón, A; Ares, I; Castellano, V; Fontecha, J; Juarez, M; Martínez, MA; Martínez-Larrañaga, MR; Rodríguez-Alcalá, LM, 2015
)
0.61
"Although several works have reported absorption rate differences of n-3 polyunsaturated fatty acids (PUFA) bound to different lipid forms, such as ethyl ester, triacylglycerol (TAG), and phospholipids, no studies have investigated the effect of n-3 PUFA from glycolipids (GL)."( Dietary ALA from Spinach Enhances Liver n-3 Fatty Acid Content to Greater Extent than Linseed Oil in Mice Fed Equivalent Amounts of ALA.
Hosokawa, M; Kamogawa, H; Kuroe, M; Miyashita, K, 2016
)
0.43
" In conclusion, ternary nanoparticles are considered promising carriers to effectively improve the bioavailability of naringin."( Structural characterization and bioavailability of ternary nanoparticles consisting of amylose, α-linoleic acid and β-lactoglobulin complexed with naringin.
Feng, T; Liu, F; Wang, K; Xu, Z; Ye, R; Zhu, X; Zhuang, H, 2017
)
0.46
" The present study was designed to prepare curcumin nanoemulsion using phospholipid core material (Lipoid™) and exploring the possibility of enhancing its bioavailability and its impact on DHA levels in rats."( Curcumin and linseed oil co-delivered in phospholipid nanoemulsions enhances the levels of docosahexaenoic acid in serum and tissue lipids of rats.
Lokesh, BR; Sugasini, D, 2017
)
0.46
"To investigate the bioavailability of heavy metal cadmium on planktonic algae under the condition of containing linolenic acid."( [Effect of linolenic acid on bioavailability of cadmium in eutrophic water].
Chen, B; Shi, M; Yan, H; Zhang, T, 2018
)
0.48
" This study aimed to determine thermal stability and bioavailability of perilla oil that was powdered by inclusion complexation with γ-cyclodextrin."( Thermal stability and bioavailability of inclusion complexes of perilla oil with γ-cyclodextrin.
Kawahara, H; Kurata, K; Narumiya, Y; Oe, S; Shimizu, H; Yamamoto, T; Yoshikiyo, K; Yoshioka, Y, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"We evaluated the impact of increasing doses of rapeseed lecithin (RL), rich in essential α-linolenic acid (ALA), on postprandial lipid metabolism and ALA bioavailability in lymph-cannulated rats."( Rapeseed Lecithin Increases Lymphatic Lipid Output and α-Linolenic Acid Bioavailability in Rats.
Buisson, C; Couëdelo, L; Errazuriz-Cerda, E; Fonseca, L; Knibbe, C; Loizon, E; Meugnier, E; Michalski, MC; Robert, C; Vaysse, C, 2020
)
0.56
"In rats, RL enhanced lymphatic lipid output, as well as the rate of appearance of ALA, which may promote its subsequent bioavailability and metabolic fate."( Rapeseed Lecithin Increases Lymphatic Lipid Output and α-Linolenic Acid Bioavailability in Rats.
Buisson, C; Couëdelo, L; Errazuriz-Cerda, E; Fonseca, L; Knibbe, C; Loizon, E; Meugnier, E; Michalski, MC; Robert, C; Vaysse, C, 2020
)
0.56
"The aim of this study was to investigate the bioavailability and bioactivity of perilla (Perilla frutescens) oil nanoemulsions prepared at different homogenization pressures by measuring the weight, fatty acid profile, and antioxidant and anti-inflammatory properties in rats."( Effect of nanoemulsion particle size on the bioavailability and bioactivity of perilla oil in rats.
Hu, M; Li, Y; Qi, B; Xie, F; Zhang, S, 2021
)
0.62
" Due to the low bioavailability of linseed oil (LINO), which is the most common ALA supplement, it is necessary to find a replacement for ALA supplements that is more easily accepted by the human body."( An alternative solution for α-linolenic acid supplements: in vitro digestive properties of silkworm pupae oil in a pH-stat system.
Wang, J; Wang, JZ; Wu, FA; Xun, XM; Yan, CH; You, S, 2021
)
0.62
" This study aimed to test the bioavailability of the oil derived from basil seeds and its effects on different physiological parameters using 7-15% dietary inclusion levels."( Bioavailability and biotransformation of linolenic acid from basil seed oil as a novel source of omega-3 fatty acids tested on a rat experimental model.
Bermúdez, F; Galisteo, M; Guzmán, A; López-Jurado, M; Martínez, R; Melguizo, C; Mesas, C; Porres, JM; Prados, J, 2022
)
0.72
"Nanoliposome encapsulation combined with carboxymethyl chitosan (CMCS) surface decoration was employed to improve physicochemical stability and oral bioavailability of alpha-linolenic acid (ALA)."( Carboxymethyl chitosan coated alpha-linolenic acid nanoliposomes: Preparation, stability and release in vitro and in vivo.
Gong, L; Li, W; Li, X; Liu, B; Meng, X; Yang, C, 2023
)
1.39

Dosage Studied

The performance of milk fat-globule membrane (MFGM) emulsion as an oral dosage form was evaluated. Cells were dosed with alpha-linolenic acid (18:3n-3), the essential metabolic precursor of the n-3 polyunsaturated fatty acid series.

ExcerptRelevanceReference
" The anti-aggregatory, anti-thrombotic and anti-inflammatory properties of omega 3 fatty acids have been confirmed, and a dose-response curve is emerging."( Summary of the NATO advanced research workshop on dietary omega 3 and omega 6 fatty acids: biological effects and nutritional essentiality.
Simopoulos, AP, 1989
)
0.28
"As a study to assess the potential application of milk fat-globule membrane (MFGM), which is of natural origin and expected to be a safer alternative to synthetic emulsifiers, to pharmaceutical dosage forms, the oral absorption of alpha-linolenic acid was evaluated by the analysis of gastrointestinal disposition after oral administration as an MFGM emulsion to rats."( Gastric emptying-limited oral absorption of alpha-linolenic acid administered as a milk fat-globule membrane (MFGM) emulsion in rats.
Ozeki, S; Sekiya, M; Watanabe, J; Yuasa, H, 1994
)
0.73
" In one of these 6 cases, the dosage of CoQ10 was increased to 390 mg."( Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10.
Folkers, K; Lockwood, K; Moesgaard, S, 1994
)
0.29
"The performance of milk fat-globule membrane (MFGM) emulsion as an oral dosage form was evaluated in rats using [14C]alpha-linolenic acid as a lipophilic model solute."( Evaluation of milk fat-globule membrane (MFGM) emulsion for oral administration: absorption of alpha-linolenic acid in rats and the effect of emulsion droplet size.
Ozeki, S; Sekiya, M; Watanabe, J; Yuasa, H, 1994
)
0.72
" The rats were fed a basal diet containing either 12% olive oil, 12% safflower oil, 12% perilla oil, 6% perilla oil plus 6% olive oil, or 3% perilla oil plus 9% olive oil for 5 weeks, starting 1 week before the first dosing of AOM."( Suppressing effect of perilla oil on azoxymethane-induced foci of colonic aberrant crypts in rats.
Kawamori, T; Komaki, C; Mori, H; Moriwaki, H; Muto, Y; Okuno, M; Onogi, N; Tanaka, T, 1996
)
0.29
" Rats and mice were dosed with deuterium-labeled linoleic and linolenic acids either by intraperitoneal injection or by gavage."( Essential fatty acid uptake and metabolism in the developing rodent brain.
Pawlosky, RJ; Salem, N; Ward, G, 1996
)
0.29
" In this experiment, sheep were dosed orally with protected PUFA (Pr-PUFA) for five weeks at 5 g kg liveweight-1 three times per week for the first week and at 8 g kg-1 for the following four weeks."( Effect of doses of protected polyunsaturated fatty acids on indicators of selenium status of sheep.
Isopenko, A; Smith, GM,
)
0.13
" At 4 wk of age, neonates were dosed with either 13C LNA or 13C DHA."( Dietary 18:3n-3 and 22:6n-3 as sources of 22:6n-3 accretion in neonatal baboon brain and associated organs.
Bernardo, L; Brenna, JT; Ma, XH; Mirmiran, M; Nathanielsz, PW; Su, HM, 1999
)
0.3
" Dose-response and time course experiments revealed a similar pattern of transcript accumulation and lipoxygenase activity in BTH-treated rice leaves."( Characterization of RCI-1, a chloroplastic rice lipoxygenase whose synthesis is induced by chemical plant resistance activators.
Dudler, R; Schaffrath, U; Zabbai, F, 2000
)
0.31
" A dose-response effect was demonstrated for LA, ALA, EPA and DHA in both J774A."( Effect of long-chain fatty acids in the culture medium on fatty acid composition of WEHI-3 and J774A.1 cells.
Babu, US; O'Donnell, MW; Wiesenfeld, PW, 2001
)
0.31
"NK mouse model to understand the histological and molecular changes associated with the dose-response pattern of mammary tumor incidence and growth after treatment with a broad range of doses of melatonin."( Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene.
Herbert, RA; Ney, E; Rao, GN, 2000
)
0.31
" The present study investigated the pattern of tissue lipid labeling following an oral dose of 1-14C-linoleic acid after the animals had been dosed for the same time as above."( 1-14C-linoleic acid distribution in various tissue lipids of guinea pigs following an oral dose.
Attar-Bashi, NM; Fu, Z; Sinclair, AJ, 2001
)
0.31
" This latter method showed that within 48 h of dosing with 13C-alpha-linolenate, >80% underwent beta-oxidation to CO2 by suckling rats, whereas 8-9% was converted to newly synthesized lipids and <1 % to docosahexaenoate."( Application of new methods and analytical approaches to research on polyunsaturated fatty acid homeostasis.
Cunnane, SC, 2001
)
0.31
"The newly synthesized linoleic acid derivative, FR236924, induces a long-lasting facilitation of hippocampal neurotransmission based on a persistent enhancement in the activity of presynaptic nicotinic ACh receptors via a PKC pathway and the ensuing increase in glutamate release, not only in vitro but in vivo at a low dosage (2mg/kg, ip), which suggested the possibility of its use as a promising anti-dementia drug."( The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
Nishizaki, T; Tanaka, A, 2003
)
0.32
" The immunological effects of more modest doses of n-3 PUFA in human subjects are unclear, dose-response relationships between n-3 PUFA supply and immune function have not been established and whether ALNA has the same effects as its long-chain derivatives is not known."( Comparison of the effects of linseed oil and different doses of fish oil on mononuclear cell function in healthy human subjects.
Calder, PC; Miles, EA; Wallace, FA, 2003
)
0.32
" Cells were dosed with alpha-linolenic acid (18:3n-3), the essential metabolic precursor of the n-3 polyunsaturated fatty acid series that normally gives rise through terminal peroxisomal oxidation to the synthesis of membrane docosahexaenoic acid (22:6n-3, or DHA)."( Docosahexaenoic acid membrane content and mRNA expression of acyl-CoA oxidase and of peroxisome proliferator-activated receptor-delta are modulated in Y79 retinoblastoma cells differently by low and high doses of alpha-linolenic acid.
Alessandri, JM; Furet, JP; Langelier, B; Perruchot, MH, 2003
)
0.82
" The present consensus is that the cardioprotection of very long chain n-3 fatty acids (also called EPA and DHA) at the low dosage used in recent secondary prevention trials primarily results from an effect on the ischemic myocardium and probably not from an effect on blood lipids and hemostasis."( Use and misuse of dietary fatty acids for the prevention and treatment of coronary heart disease.
De Lorgeril, M; Salen, P,
)
0.13
" Thus, on a per dosage basis, the total amounts of n-3 and n-6 end products accreted in plasma were considerably greater for C20 EFA precursors relative to C18."( In vivo conversion of 18- and 20-C essential fatty acids in rats using the multiple simultaneous stable isotope method.
Lin, YH; Salem, N, 2005
)
0.33
"Irinotecan hydrochloride (CPT-11), a topoisomerase I inhibitor highly effective for various cancers, has its dosage limited by diffuse mucosal damage with increased prostaglandin (PG) E(2)."( Phospholipid fatty acid composition and diamine oxidase activity of intestinal mucosa from rats treated with irinotecan hydrochloride (CPT-11) under vegetable oil-enriched diets: comparison between perilla oil and corn oil.
Aoyama, M; Fueda, Y; Kishimoto, K; Miyoshi, M; Ohata, A; Ohmae, K; Usami, M,
)
0.13
" Directions for future research include (1) RCTs to confirm the initial trials showing that EPA plus DHA decreases cardiovascular death and additional studies to determine whether this effect is due to EPA, DHA, or the combination; the dosage of the effective components; and whether the mechanism of action in humans is prevention of fatal arrhythmias."( n-3 fatty acids and cardiovascular disease.
Breslow, JL, 2006
)
0.33
" On average, approximately 16-18% of the D5-18:3n-3 and D5-18:2n-6 initial dosage was eventually accumulated in tissues, principally in adipose, skin, and muscle."( Whole body distribution of deuterated linoleic and alpha-linolenic acids and their metabolites in the rat.
Lin, YH; Salem, N, 2007
)
0.59
" Although flax oil may decrease severity of illness in children and adolescents with bipolar disorder who have meaningful increases in serum EPA percent levels and/or decreased AA and DPA n-6 levels, individual variations in conversion of alpha-LNA to EPA and docosahexaenoic acid as well as dosing burden favor the use of fish oil both for clinical trials and clinical practice."( Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder.
Chirieac, MC; Costescu, S; Finucane, TL; Gracious, BL; Hibbeln, JR; Youngstrom, EA, 2010
)
0.36
" Secondary measures include: requirement for surgical interventions, exercise and cardiopulmonary performance, cardiac arrhythmias, serum lipid profile, arterial sufficiency, blood pressure, inflammatory profile, platelet function, changes in drug dosage levels, as well as nutrigenomic and biomarker profiles in the blood."( The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX-PAD randomized controlled trial.
Aliani, M; Guzman, R; Leyva, DR; Pierce, GN; Ramjiawan, B; Zahradka, P, 2011
)
0.37
" They also show that increasing the dosage of the FAD3-containing genomic region results in an increase in the linolenic acid content of seed oil."( Two high linolenic mutants of Arabidopsis thaliana contain megabase-scale genome duplications encompassing the FAD3 locus.
Baker, D; Bancroft, I; Bennett, G; Clarke, J; O'Neill, CM, 2011
)
0.37
" A dose-response study with ALA showed that the activity of the mitochondrial succinate dehydrogenase enzyme was suppressed at all concentrations of glucose tested to a significant degree."( Effect of essential fatty acids on glucose-induced cytotoxicity to retinal vascular endothelial cells.
Das, UN; Shen, J; Shen, S; Xu, G, 2012
)
0.38
"To investigate the association between intake of fish and n-3 polyunsaturated fatty acids (n-3 PUFA) and the risk of breast cancer and to evaluate the potential dose-response relation."( Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies.
Hu, XJ; Li, D; Yang, J; Zhao, YM; Zheng, JS, 2013
)
0.39
"After adjustment for age, sex, and other confounders, negative dose-response associations between the contents of individual n-3 polyunsaturated fatty acids in the erythrocyte membrane and the prevalence of carotid artery wall thickening and plaque were observed."( Erythrocyte membrane n-3 fatty acid levels and carotid atherosclerosis in Chinese men and women.
Chen, CG; Chen, YM; Dai, XW; Su, YX; Wang, P; Zhang, B, 2014
)
0.4
" We therefore examined dose-response relationships between fatty acids and PPARα transactivation in HepG2 cells."( Fatty acid chain length and saturation influences PPARα transcriptional activation and repression in HepG2 cells.
Konings, M; Mensink, RP; Plat, J; Popeijus, HE; Serbonij, K; van der Krieken, SE; van Otterdijk, SD, 2014
)
0.4
" Four hours after the last dosing on day 10, plasma was collected and analyzed with high-performance, dual chromatography-Fourier-transform mass spectrometry that was followed by biostatistical and bioinformatic analyses."( Short-term oral atrazine exposure alters the plasma metabolome of male C57BL/6 mice and disrupts α-linolenate, tryptophan, tyrosine and other major metabolic pathways.
Filipov, NM; He, C; Jones, DP; Lin, Z; Roede, JR, 2014
)
0.4
" However, the effects of this dosing schedule administered after a brain insult and the underlying molecular mechanisms in the hippocampus are unknown."( Alpha-Linolenic Acid-Induced Increase in Neurogenesis is a Key Factor in the Improvement in the Passive Avoidance Task After Soman Exposure.
Apland, JP; Chen, J; Grunberg, N; Marini, AM; McDonough, J; Pan, H; Piermartiri, TC, 2015
)
1.86
" This dosing schedule significantly reduced soman-induced neuronal degeneration in four major vulnerable brain regions up to 21 days."( Repeated systemic administration of the nutraceutical alpha-linolenic acid exerts neuroprotective efficacy, an antidepressant effect and improves cognitive performance when given after soman exposure.
Black, K; Chen, J; Driwech, W; Figueiredo, T; Grunberg, N; Marini, AM; McDonough, J; McFarland, E; Oppel, C; Pan, H; Piermartiri, TC; Winter, K, 2015
)
0.67
"A comparison between a soybean oil lipid emulsion (Intralipid group A) and POLE with high (group B) versus low (group C) levels of phytosterols was made with regard to their effects on the general condition, hematological and biochemical parameters, urinalysis and histopathological changes in nine dogs receiving daily infusions for four weeks at dosage levels of 6, 6, 9 g fat /kg."( Evaluating the safety of phytosterols removed perilla seed oil-based lipid emulsion.
Guo, H; He, H; Huang, C; Li, W; Liu, D; Lu, D; Ren, T; Tang, X; Yang, Z, 2016
)
0.43
" We aimed to examine an aggregate association between ALA intake and risk of CHD, and assess for any dose-response relationship."( The association and dose-response relationship between dietary intake of α-linolenic acid and risk of CHD: a systematic review and meta-analysis of cohort studies.
Ali, MK; Chandrasekar, EK; Hou, R; Hu, Y; Kowalski, A; Sun, H; Wang, T; Wei, J; Xi, Y; Yu, Z, 2018
)
0.48
" However, to be utilised as biomarkers, to predict dietary intake, dose-response curves that cover a spectrum of intakes are required."( Effect of supplementation with flaxseed oil and different doses of fish oil for 2 weeks on plasma phosphatidylcholine fatty acids in young women.
Crowe, FL; Hodson, L; McLachlan, KJ; Skeaff, CM, 2018
)
0.48
" We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression."( Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid, AS; AlAbdulghafoor, FK; Biswas, P; Brainard, JS; Brown, TJ; Deane, KH; Hooper, L; Moore, HJ; Song, F; Summerbell, CD; Thorpe, GC; Worthington, HV, 2018
)
0.48
" We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression."( Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid, AS; AlAbdulghafoor, FK; Biswas, P; Brainard, JS; Brown, TJ; Deane, KH; Hooper, L; Moore, HJ; Song, F; Summerbell, CD; Thorpe, GC; Worthington, HV, 2018
)
0.48
" We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression."( Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid, AS; Biswas, P; Brainard, JS; Brown, TJ; Deane, KH; Hooper, L; Moore, HJ; Song, F; Summerbell, CD; Thorpe, GC; Worthington, HV, 2020
)
0.56
" We demonstrated a substantial metabolic disparity between the dosing and control groups, further verifying the reliability of the method."( Effect of Short-Chain Fatty Acids and Polyunsaturated Fatty Acids on Metabolites in H460 Lung Cancer Cells.
Fu, W; Huang, J; Wang, Y; Yan, C; Yang, K; Zhou, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (39 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care14
Vitamins & Supplements15
Active Lifestyle & Fitness1
Herbs, Botanicals & Homeopathy2
Pet Supplies5
Food & Beverages2

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Acure Radically Rejuvenating Whipped Night Cream -- 1.7 fl ozAcureBeauty & Personal CarePCA, linolenic acid, vitamin C, aspartic acid, cetearyl alcohol, ferulic acid, glycerin, linoleic acid2024-11-29 10:47:42
Acure Ultra Hydrating Electrolyte Facial Moisturizer -- 1.7 fl ozAcureBeauty & Personal Carelinolenic acid, calcium PCA, cetearyl alcohol, tocopherol, tocopherol, glycerin, linoleic acid, glyceryl laurate, glyceryl caprylate, squalane2024-11-29 10:47:42
Alba Botanica Hawaiian Conditioner Body Builder Mango -- 32 ozAlbaBeauty & Personal Carecitric acid, linolenic acid, benzyl alcohol, cetearyl alcohol, cetyl alcohol, citric acid, panthenol, glycerin, dimethicone, limonene, linoleic acid, phenoxyethanol, retinyl palmitate, sodium benzoate, stearyl alcohol2024-11-29 10:47:42
Alba Botanica Hawaiian Shampoo Body Builder Mango -- 32 fl ozAlbaBeauty & Personal Carecitric acid, linolenic acid, ascorbic acid, benzoic acid, benzyl alcohol, citric acid, cocamidopropyl betaine, tocopherol, dehydroacetic acid, panthenol, tocopherol, glycerin, limonene, retinyl palmitate, sodium benzoate, sodium citrate, sodium sulfate2024-11-29 10:47:42
Alba Botanica® Body Builder Shampoo Mango -- 12 fl ozAlbaBeauty & Personal Carecitric acid, linolenic acid, ascorbic acid, benzoic acid, benzyl alcohol, citric acid, tocopherol, dehydroacetic acid, panthenol, tocopherol, glycerin, limonene, linoleic acid, phenoxyethanol, retinyl palmitate, sodium benzoate2024-11-29 10:47:42
Ancient Nutrition Omegas Whole Body -- 1000 mg - 90 SoftgelsAncient NutritionVitamins & SupplementsAlpha-Linolenic Acid, Astaxanthin, Docosahexaenoic Acid2024-11-29 10:47:42
Animal Advanced Omega -- 30 PacksAnimalActive Lifestyle & FitnessAlpha-Linolenic Acid, Vitamin E, Docosahexaenoic Acid, Gamma Linolenic Acid, Vitamin E2024-11-29 10:47:42
Balanceuticals Seabuckthorn Seed Oil -- 500 mg - 60 SoftgelsBalanceuticalsHerbs, Botanicals & HomeopathyLinolenic Acid, Vitamin E, Vitamin E, Linoleic acid, Oleic Acid, Vitamin A2024-11-29 10:47:42
Bluebonnet Nutrition Super Earth Lecithin Granules Natural Soya -- 25.4 ozBluebonnet NutritionVitamins & SupplementsLinolenic Acid, Choline, Inositol, Linoleic Acid, Phosphorus2024-11-29 10:47:42
Ceramedx Gentle Foaming Facial Cleanser -- 8 fl ozCeramedxBeauty & Personal Carecitric acid, allantoin, linolenic acid, ceramide np, citric acid, tocopherol, tocopherol, glycerin, linoleic acid, maltodextrin, sodium lauroyl sarcosinate2024-11-29 10:47:42
Ceramedx Soothing Facial Lotion Fragrance Free -- 4 fl ozCeramedxBeauty & Personal Careglyceryl oleate, allantoin, linolenic acid, ascorbic acid, ceramide np, cetearyl alcohol, tocopherol, dl-panthenol, ethylhexylglycerin, tocopherol, glyceryl stearate, glycerin, dimethicone, linoleic acid, maltodextrin2024-11-29 10:47:42
Chew + Heal Omega Skin + Coat Supplement for Dogs Peanut Butter -- 180 Soft ChewsChew + HealPet Suppliesalpha-Linolenic Acid, EPA, Linoleic Acid2024-11-29 10:47:42
Country Life Ultra Concentrated Omega™ 3 6 9 -- 90 SoftgelsCountry LifeVitamins & SupplementsAlpha-Linolenic Acid, Vitamin E, Docosahexaenoic Acid, Vitamin E, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Deva Vegan Hemp Seed Oil -- 90 Vegan CapsDevaVitamins & SupplementsLinolenic Acid, Oleic Acid2024-11-29 10:47:42
Fearn Lecithin Granules -- 16 ozFearnVitamins & SupplementsLinolenic Acid, Choline, Vitamin E, Folic Acid, Vitamin E, Linoleic Acid, Niacin, Fat, Phosphorus, Riboflavin, Thiamine, Vitamin B122024-11-29 10:47:42
Greens First PRO Ahiflower Oil Vegan Omega-3 -- 90 SoftgelsGreens FirstVitamins & SupplementsLinolenic Acid, Stearidonic Acid, Gamma Linolenic Acid, glycerin, Oleic Acid, tocopherols2024-11-29 10:47:42
Healthy Pup Healthy Skin Omega Supplement for Dogs -- 180 Soft ChewsHealthy PupPet Suppliesalpha-Linolenic Acid, EPA, glycerin, Linoleic Acid, maltodextrin, sorbic acid2024-11-29 10:47:42
Healthy Pup Multi Max for Dogs -- 120 Soft ChewsHealthy PupPet Suppliescitric acid, alpha-Linolenic Acid, Biotin, Calcium Ascorbate, dicalcium phosphate, Vitamin D3, Choline, citric acid, Cobalt, copper carbonate, Vitamin E, ferrous sulfate, folic acid, Vitamin E, glycerin, Iodine, Linoleic Acid, maltodextrin, Manganese, Niacin, Oleic Acid, d-Pantothenic Acid, Phosphorus, potassium iodide, pyridoxine hydrochloride, Pyridoxine, vitamin A palmitate, Vitamin A, Riboflavin, sorbic acid, Thiamine, Vitamin B12, Menadione, zinc sulfate2024-11-29 10:47:42
Jason Extra Volumizing Biotin Conditioner -- 8 fl ozJasonBeauty & Personal Careisopropyl alcohol, citric acid, ascorbyl palmitate, linolenic acid, benzyl alcohol, biotin, cetearyl alcohol, cetyl alcohol, citric acid, panthenol, triethyl citrate, glycerin, linoleic acid, maltodextrin, menthol, phenoxyethanol, phenethyl alcohol, stearyl alcohol2024-11-29 10:47:42
Jason Intense Moisture Conditioner Aloe Vera + Prickly Pear -- 16 fl ozJasonBeauty & Personal Careisopropyl alcohol, phytantriol, citric acid, ascorbyl palmitate, linolenic acid, terpineol, benzyl alcohol, betaine, cetearyl alcohol, cetyl alcohol, citric acid, panthenol, triethyl citrate, glycerin, linoleic acid, phenoxyethanol, phenethyl alcohol, stearyl alcohol2024-11-29 10:47:42
Jason Purifying Tea Tree Conditioner -- 12 fl ozJasonBeauty & Personal Careisopropyl alcohol, citric acid, linolenic acid, terpineol, benzyl alcohol, cetearyl alcohol, cetyl alcohol, citric acid, tocopherol, panthenol, triethyl citrate, tocopherol, glycerin, linoleic acid, phenethyl alcohol, stearyl alcohol2024-11-29 10:47:42
Manitoba Harvest Hemp Seed Oil -- 120 SoftgelsManitoba HarvestVitamins & SupplementsAlpha-Linolenic Acid, Omega-3, Stearidonic Acid, Gamma Linoleic Acid, glycerin2024-11-29 10:47:42
Manitoba Harvest Hemp Seed Oil -- 780 mg - 60 Softgel CapsulesManitoba HarvestVitamins & SupplementsAlpha-Linolenic Acid, Omega-3, Stearidonic Acid, Gamma Linolenic Acid, glycerin2024-11-29 10:47:42
Manitoba Harvest Organic Hemp Seed Oil -- 16.9 fl ozManitoba HarvestFood & BeveragesAlpha-Linolenic Acid, Stearidonic Acid, Gamma Linolenic Acid2024-11-29 10:47:42
Manitoba Harvest Organic Hemp Seed Oil -- 8.45 fl ozManitoba HarvestFood & BeveragesAlpha-Linolenic Acid, Stearidonic Acid, Gamma Linolenic Acid2024-11-29 10:47:42
Mason Natural Flaxseed Oil - Omega 3-6-9 -- 1000 mg - 100 SoftgelsMason NaturalVitamins & SupplementsAlpha-Linolenic Acid, glycerin, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Natrol Omega 3-6-9 Complex Lemon -- 1200 mg - 60 SoftgelsNatrolVitamins & SupplementsAlpha-Linolenic Acid, EPA, glycerin, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Natrol Omega 3-6-9 Complex Heart Health Lemon -- 90 SoftgelsNatrolVitamins & SupplementsAlpha-Linolenic Acid, EPA, glycerin, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Seabuck Wonders Omega 7 Complete™ -- 500 mg - 60 SoftgelsSeabuck WondersVitamins & SupplementsLinolenic Acid, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Seabuck Wonders Organic Himalayan SeaBuckthorn Seed Oil -- 1 fl ozSeabuck WondersHerbs, Botanicals & HomeopathyLinolenic Acid, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Seabuck Wonders Sea Buckthorn Oil Blend Omega-7 Complete -- 500 mg - 120 SoftgelsSeabuck WondersVitamins & SupplementsLinolenic Acid, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Seabuck Wonders Sea Buckthorn Seed Oil -- 500 mg - 60 SoftgelsSeabuck WondersVitamins & SupplementsLinolenic Acid, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Sundown Naturals Triple Omega 3-6-9 VALUE SIZE -- 200 SoftgelsSundown NaturalsVitamins & SupplementsAlpha-Linolenic Acid, Docosahexaenoic Acid, Gamma Linolenic Acid, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
The Honest Company Tinted Lip Lip Balm - Blood Orange -- 0.141 ozThe Honest CompanyBeauty & Personal Carecitric acid, linolenic acid, citric acid, tocopherol, tocopherol, linoleic acid, oleic acid, titanium dioxide2024-11-29 10:47:42
The Honest Company Tinted Lip Lip Balm - Dragon Fruit -- 0.141 ozThe Honest CompanyBeauty & Personal Carecitric acid, linolenic acid, citric acid, tocopherol, tocopherol, linoleic acid, oleic acid, titanium dioxide2024-11-29 10:47:42
The Honest Company Tinted Lip Lip Balm - Plum Drop -- 0.141 ozThe Honest CompanyBeauty & Personal Carecitric acid, linolenic acid, citric acid, tocopherol, tocopherol, linoleic acid, oleic acid, titanium dioxide2024-11-29 10:47:42
The Honest Company Tinted Lip Lip Balm - Summer Melon -- 0.141 ozThe Honest CompanyBeauty & Personal Carecitric acid, linolenic acid, citric acid, tocopherol, tocopherol, linoleic acid, oleic acid, titanium dioxide2024-11-29 10:47:42
Zesty Paws All-In-One Training Bites for Dogs Bacon -- 8 ozZesty PawsPet Suppliescitric acid, alpha-linolenic acid, citric acid, docosahexaenoic acid, linoleic acid, max2024-11-29 10:47:42
Zesty Paws All-In-One Training Bites for Dogs Peanut Butter -- 8 ozZesty PawsPet Suppliescitric acid, alpha-linolenic acid, citric acid, docosahexaenoic acid, linoleic acid, max2024-11-29 10:47:42

Roles (3)

RoleDescription
micronutrientAny nutrient required in small quantities by organisms throughout their life in order to orchestrate a range of physiological functions.
nutraceuticalA product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
linolenic acidA two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.
omega-3 fatty acidA family of polyunsaturated fatty acids that have in common a final carbon-carbon double bond in the omega-3 position, i.e., the third bond from the methyl end of the fatty acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (417)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism1041
alpha-linolenic acid (ALA) metabolism1031
Alpha Linolenic Acid and Linoleic Acid Metabolism517
Triacylglycerol Degradation TG(16:0/16:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(16:0/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:0)513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/20:0)513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/22:0)513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(16:0/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/20:0)513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/22:0)513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:0/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:1(11Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/16:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:1(11Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:1(13Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:1(13Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/20:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/20:1(11Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:3(9Z,12Z,15Z))58
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/22:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:0/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/22:0)513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/20:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(20:0/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(20:0/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(20:1(11Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/18:3(9Z,12Z,15Z))58
Triacylglycerol Degradation TG(20:1(13Z)/22:0/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(22:0/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(22:0/22:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(22:0/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(22:1(13Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))512
Metabolism of alpha-linolenic acid615
Omega-3 / omega-6 fatty acid synthesis038
Jasmonic Acid Biosynthesis933
alpha-Linolenic Acid Metabolism1020
ALA oxylipin metabolism011
Mitochondrial beta-oxidation064
Elongation of (very) long chain fatty acids345
Folic acid network070
AtMetExpress overview0109
Selenium micronutrient network095
Omega-3 and omega-6 unsaturated fatty acids biosynthesis pathway014
Jasmonate biosynthesis216
9-LOX and 9-HPL pathway03
13-LOX and 13-HPL pathway08

Protein Targets (96)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency14.97630.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency6.96220.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency22.41130.044717.8581100.0000AID485294; AID485341
Chain A, HADH2 proteinHomo sapiens (human)Potency12.58930.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency12.58930.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.95260.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency20.79450.125919.1169125.8920AID2549
Chain A, CruzipainTrypanosoma cruziPotency19.11800.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency88.55710.007215.758889.3584AID1224835
thioredoxin reductaseRattus norvegicus (Norway rat)Potency79.43280.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency0.12590.012610.691788.5700AID887
WRNHomo sapiens (human)Potency17.78280.168331.2583100.0000AID651768
phosphopantetheinyl transferaseBacillus subtilisPotency67.83350.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency61.65243.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.30640.006038.004119,952.5996AID1159521
SMAD family member 2Homo sapiens (human)Potency49.29710.173734.304761.8120AID1346859; AID1346924
USP1 protein, partialHomo sapiens (human)Potency53.17640.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency22.38720.35487.935539.8107AID624170
SMAD family member 3Homo sapiens (human)Potency49.29710.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency28.39070.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency27.34270.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency34.77630.000221.22318,912.5098AID743035; AID743036; AID743042; AID743054
thioredoxin glutathione reductaseSchistosoma mansoniPotency35.48130.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency11.97840.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency67.96230.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency60.57150.000417.946075.1148AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency8.96640.531815.435837.6858AID504845
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.76210.000214.376460.0339AID588532; AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency44.64040.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.27760.000817.505159.3239AID1159527; AID588544
farnesoid X nuclear receptorHomo sapiens (human)Potency50.73160.375827.485161.6524AID588527; AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency61.13060.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency37.05470.000229.305416,493.5996AID743069; AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency41.88030.001024.504861.6448AID588534; AID588535; AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency26.54890.001019.414170.9645AID588536; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency30.89940.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.98330.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency54.48270.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency53.03480.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency19.496219.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency43.64650.057821.109761.2679AID1159526; AID1159528
Caspase-7Cricetulus griseus (Chinese hamster)Potency76.95880.006723.496068.5896AID1346980
Bloom syndrome protein isoform 1Homo sapiens (human)Potency39.81070.540617.639296.1227AID2528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency34.58010.354828.065989.1251AID504847
caspase-3Cricetulus griseus (Chinese hamster)Potency76.95880.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency60.83990.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency38.41140.042027.378961.6448AID743210; AID743228
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency16.83360.168316.404067.0158AID720504
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency47.30130.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency25.11890.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency15.93870.100028.9256213.3130AID588591; AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency21.26210.050127.073689.1251AID588590; AID720496
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency31.62280.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency4.10950.004611.374133.4983AID624296
DNA polymerase kappa isoform 1Homo sapiens (human)Potency13.35040.031622.3146100.0000AID588579; AID720501
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency10.00000.251215.843239.8107AID504327
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency26.60860.058010.694926.6086AID588379
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency22.38720.025911.239831.6228AID602313
lamin isoform A-delta10Homo sapiens (human)Potency22.38720.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency14.12540.316212.765731.6228AID881
Cellular tumor antigen p53Homo sapiens (human)Potency61.13060.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency14.12540.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency31.62280.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phospholipase A2 precursorHomo sapiens (human)IC50 (µMol)22.30001.02009.002515.2000AID588400
cysteine protease ATG4B isoform aHomo sapiens (human)IC50 (µMol)15.30001.250010.663219.1000AID504756
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)93.00000.00051.41288.2000AID360928
TrypsinSus scrofa (pig)IC50 (µMol)200.00000.50000.50000.5000AID402793
Coagulation factor VIIHomo sapiens (human)IC50 (µMol)30.00000.00020.83363.3000AID402795
AromataseHomo sapiens (human)IC50 (µMol)44.20000.00001.290410.0000AID376617
Tissue factorHomo sapiens (human)IC50 (µMol)30.00000.00010.734410.0000AID402795
Prostaglandin G/H synthase 1Homo sapiens (human)Ki4.00000.00301.37704.0000AID1053273
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)12.00000.00101.453910.0000AID360927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Free fatty acid receptor 1Homo sapiens (human)EC50 (µMol)5.06730.00030.73698.8000AID1290695; AID1420968; AID347387; AID673112
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)1.25100.00203.519610.0000AID1215087; AID1215094
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)Kd2.00000.00120.95314.9800AID677050
Free fatty acid receptor 4Homo sapiens (human)EC50 (µMol)2.91800.04372.35477.5858AID347386; AID673111
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (284)

Processvia Protein(s)Taxonomy
phospholipase C-activating G protein-coupled receptor signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationFree fatty acid receptor 1Homo sapiens (human)
insulin secretionFree fatty acid receptor 1Homo sapiens (human)
negative regulation of interleukin-1 beta productionFree fatty acid receptor 1Homo sapiens (human)
glucose homeostasisFree fatty acid receptor 1Homo sapiens (human)
positive regulation of calcium ion transportFree fatty acid receptor 1Homo sapiens (human)
response to fatty acidFree fatty acid receptor 1Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
ligand-gated ion channel signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
positive regulation of insulin secretionFree fatty acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayFree fatty acid receptor 1Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cytokine productionFree fatty acid receptor 4Homo sapiens (human)
inflammatory responseFree fatty acid receptor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayFree fatty acid receptor 4Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayFree fatty acid receptor 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationFree fatty acid receptor 4Homo sapiens (human)
regulation of glucose transmembrane transportFree fatty acid receptor 4Homo sapiens (human)
negative regulation of interleukin-1 beta productionFree fatty acid receptor 4Homo sapiens (human)
ghrelin secretionFree fatty acid receptor 4Homo sapiens (human)
negative regulation of apoptotic processFree fatty acid receptor 4Homo sapiens (human)
positive regulation of osteoblast differentiationFree fatty acid receptor 4Homo sapiens (human)
negative regulation of inflammatory responseFree fatty acid receptor 4Homo sapiens (human)
white fat cell differentiationFree fatty acid receptor 4Homo sapiens (human)
brown fat cell differentiationFree fatty acid receptor 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of tasteFree fatty acid receptor 4Homo sapiens (human)
positive regulation of glucagon secretionFree fatty acid receptor 4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFree fatty acid receptor 4Homo sapiens (human)
negative regulation of somatostatin secretionFree fatty acid receptor 4Homo sapiens (human)
positive regulation of brown fat cell differentiationFree fatty acid receptor 4Homo sapiens (human)
positive regulation of cold-induced thermogenesisFree fatty acid receptor 4Homo sapiens (human)
cellular response to hormone stimulusFree fatty acid receptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayFree fatty acid receptor 4Homo sapiens (human)
hormone secretionFree fatty acid receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (79)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityFree fatty acid receptor 1Homo sapiens (human)
lipid bindingFree fatty acid receptor 1Homo sapiens (human)
bioactive lipid receptor activityFree fatty acid receptor 1Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor activityFree fatty acid receptor 4Homo sapiens (human)
fatty acid bindingFree fatty acid receptor 4Homo sapiens (human)
taste receptor activityFree fatty acid receptor 4Homo sapiens (human)
peptide bindingFree fatty acid receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
plasma membraneFree fatty acid receptor 1Homo sapiens (human)
plasma membraneFree fatty acid receptor 1Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
lysosomal membraneFree fatty acid receptor 4Homo sapiens (human)
plasma membraneFree fatty acid receptor 4Homo sapiens (human)
ciliumFree fatty acid receptor 4Homo sapiens (human)
endosome membraneFree fatty acid receptor 4Homo sapiens (human)
endocytic vesicleFree fatty acid receptor 4Homo sapiens (human)
ciliary membraneFree fatty acid receptor 4Homo sapiens (human)
plasma membraneFree fatty acid receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (133)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID720501qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds2012PloS one, , Volume: 7, Issue:10
A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1090890Phytotoxic activity against Lactuca sativa (lettuce) seeds assessed as inhibition of germination at 10 uM at 26 degC measured 7 days post-drug dose2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID347389Agonist activity at human GPR40 expressed in T-REx HEK293 cells assessed as accumulation of phosphorylated ERK1/2 at 10 to 100 uM by Western blotting2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists.
AID402799Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with tissue factor for 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID402795Inhibition of amidolytic activity of human tissue factor/human factor 7a1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID1678494Neurotoxicity in rat primary Cerebellar granule neurone assessed as cell viability at 25 uM measured after 24 hrs by MTT assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID627877Inhibition of calf DNA polymerase alpha using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1090877Antifungal activity against Colletotrichum acutatum assessed as diameter of growth inhibitory zone at 10 ug after 4-5 days by direct bioautography2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID627876Inhibition of C-terminal His6-tagged human DNA polymerase kappa (amino acids 1 to 560) using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1519391Antibacterial activity against Staphylococcus aureus NCTC 4163 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1678488Neuroprotective activity against glutamate/glycine-induced excitotoxicity in rat primary Cerebellar granule neurone at 25 uM preincubated for 6 hrs measured after 24 hrs by MTT assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID1616997Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 22019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID1678503Cytotoxicity against mouse Oli-neu cells assessed as cell viability at 0.5 uM measured after 24 hrs by MTT assay (Rvb = 100 +/- 6%)2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID1090892Phytotoxic activity against Agrostis stolonifera seeds assessed as inhibition of germination at 1000 uM at 26 degC measured 12 days post-drug dose2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID673122Agonist activity at FFAR1 expressed in HEK 293 cells assessed as beta-arrestin recruitment after 30 mins by BRET assay relative to TUG-4242012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of a potent and selective GPR120 agonist.
AID360928Inhibition of bovine COX1-mediated prostaglandin biosynthesis using [1-14C]arachidonic acid2001Journal of natural products, Jun, Volume: 64, Issue:6
Cox-2 inhibitory effects of naturally occurring and modified fatty acids.
AID145835Effect on Torpedo nicotinic ACh receptor responses at 10 min determined by measuring percentage of original amplitude2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
AID376617Inhibition of aromatase in human placental microsomes by radiometric method2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID627979Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha secretion at 5 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID658590Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as modulation of rifampicin-mediated antibacterial activity measuring reduction in MIC at 1/2 of MIC after 72 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID1420968Agonist activity at recombinant human GPR40 expressed in HEK293 cells assessed as increase in intracellular calcium flux measured for 120 secs by calcium-5 dye based assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
AID1879362Antiinflammatory activity in C57BL/6 mouse microglial BV-2 cells assessed as reduction in LPS induced TNF-alpha mRNA expression level at 100 umol/L pretreated for 3 hrs followed by LPS stimulation and measured after 24 hrs by qRT-PCR analysis2022European journal of medicinal chemistry, Mar-05, Volume: 231Linotrins: Omega-3 oxylipins featuring an E,Z,E conjugated triene motif are present in the plant kingdom and alleviate inflammation in LPS-challenged microglial cells.
AID1519398Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519395Antibacterial activity against Enterococcus hirae ATCC 10541 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1090872Antitermite activity against greater than third-instar stage of Coptotermes formosanus workers/1 soldier in compound-pretreated filter paper assessed as mortality at 0.5% at 26 degC after 13 days (Rvb = 3.8 +/-4.8%)2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID673112Agonist activity at FFAR1 expressed in HEK 293 cells assessed as beta-arrestin recruitment after 30 mins by BRET assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of a potent and selective GPR120 agonist.
AID1053268Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID402793Inhibition of pig pancreatic trypsin after 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID360929Selectivity ratio for IC50 for sheep COX2 to IC50 for bovine COX22001Journal of natural products, Jun, Volume: 64, Issue:6
Cox-2 inhibitory effects of naturally occurring and modified fatty acids.
AID347391Selectivity index, ratio of EC50 for human GPR40 to EC50 for human GPR1202008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists.
AID658577Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as modulation of rifampicin-mediated antibacterial activity measuring ratio of rifampicin MIC to rifampicin and compound MIC at 4 mg/L after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID1519397Antibacterial activity against Escherichia coli NCTC 8196 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID347384Agonist activity at human GPR120-G-alpha-16 fusion protein expressed in Flp-in HEK293 cells assessed as effect on intracellular calcium concentration at 10 uM by FLIPR assay relative to alpha-linoleic acid2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists.
AID658589Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as modulation of EtBr-mediated antibacterial activity measuring reduction in MIC at 1/2 of MIC after 72 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID1090871Antitermite activity against greater than third-instar stage of Coptotermes formosanus workers/1 soldier in compound-pretreated filter paper assessed as mortality at 0.5% at 26 degC after 21 days (Rvb = 3.8 +/-4.8%)2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID1090870Antitermite activity against greater than third-instar stage of Coptotermes formosanus workers/1 soldier in compound-pretreated filter paper assessed as filter paper consumption at 0.5% at 26 degC after 21 days (Rvb = 41.4 +/-5.6 mg)2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID1290695Agonist activity at human FFA1 receptor expressed in human 1321N1 cells measured for 50 intervals of 0.4 secs by calcium mobilization assay2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy.
AID347385Agonist activity at human GPR40 expressed in T-REx HEK293 cells assessed as effect on intracellular calcium concentration at 10 uM by FLIPR assay relative to alpha-linoleic acid2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists.
AID1678493Neurotoxicity in rat primary Cerebellar granule neurone assessed as cell viability at 10 uM measured after 24 hrs by MTT assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID1090876Antifungal activity against Colletotrichum fragariae assessed as growth inhibition at 10 ug after 4-5 days by direct bioautography2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID627981Cytotoxicity against mouse RAW264.7 cells2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1678495Neurotoxicity in rat primary Cerebellar granule neurone assessed as cell viability at 50 uM measured after 24 hrs by MTT assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID574406Cytotoxicity against human HaCaT cells at 50 to 100 uM after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads.
AID1879361Antiinflammatory activity in C57BL/6 mouse microglial BV-2 cells assessed as reduction in LPS induced IL-6 mRNA expression level at 100 umol/L pretreated for 3 hrs followed by LPS stimulation and measured after 24 hrs by qRT-PCR analysis2022European journal of medicinal chemistry, Mar-05, Volume: 231Linotrins: Omega-3 oxylipins featuring an E,Z,E conjugated triene motif are present in the plant kingdom and alleviate inflammation in LPS-challenged microglial cells.
AID627878Inhibition of histidine-tagged human DNA polymerase gamma using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID658437Antibacterial activity against Mycobacterium smegmatis mc2 155 after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID1090875Antifungal activity against Colletotrichum gloeosporioides assessed as growth inhibition at 10 ug after 4-5 days by direct bioautography2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID574405Antiinflammatory activity against IFN-gamma-stimulated human HaCaT cells assessed as inhibition of chemokine MDC production at 50 to 100 uM after 18 hrs by ELISA2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads.
AID376615Inhibition of aromatase in human placental microsomes at 20 ug/ml by radiometric method relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID627982Antiinflammatory activity in mouse assessed as inhibition of TPA-induced mouse ear edema at 500 ug/ear administered 30 mins before TPA challenge measured after 7 hrs relative to untreated control2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID347387Agonist activity at human GPR40 expressed in T-REx HEK293 cells assessed as effect on intracellular calcium concentration by FLIPR assay2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists.
AID1519393Antibacterial activity against Staphylococcus aureus ATCC 6538 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID627980Cytotoxicity against mouse RAW264.7 cells at 5 uM2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID145834Effect on Torpedo nicotinic ACh receptor responses at 0 min determined by measuring percentage of original amplitude2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
AID673123Agonist activity at GPR120 expressed in HEK 293 cells assessed as beta-arrestin recruitment after 5 mins by BRET assay relative to TUG-4242012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of a potent and selective GPR120 agonist.
AID424805Agonist activity at human PPARgamma ligand binding domain expressed in MEF cells co-transfected with Gal4-responsive luciferase vector assessed as photinus/renilla luciferase activity at 40 uM by transactivation assay relative to control2009Journal of natural products, May-22, Volume: 72, Issue:5
Activation of PPARgamma by metabolites from the flowers of purple coneflower (Echinacea purpurea).
AID1519396Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID402794Octanol-water partition coefficient, log P of the compound1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID330320Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of fetal calf serum assessed viral RNA level at 0.1 mM by RT-PCR relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID1090893Phytotoxic activity against Agrostis stolonifera seeds assessed as inhibition of germination at 100 uM at 26 degC measured 12 days post-drug dose2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID1678505Cytotoxicity against mouse Oli-neu cells assessed as cell viability at 5 uM measured after 24 hrs by MTT assay (Rvb = 100 +/- 6%)2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID376618Inhibition of aromatase in human SKBR3 cells at 100 uM relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1879360Antiinflammatory activity in C57BL/6 mouse microglial BV-2 cells assessed as reduction in LPS induced IL-1 beta mRNA expression level at 100 umol/L pretreated for 3 hrs followed by LPS stimulation and measured after 24 hrs by qRT-PCR analysis2022European journal of medicinal chemistry, Mar-05, Volume: 231Linotrins: Omega-3 oxylipins featuring an E,Z,E conjugated triene motif are present in the plant kingdom and alleviate inflammation in LPS-challenged microglial cells.
AID1678506Cytotoxicity against mouse Oli-neu cells assessed as cell viability at 10 uM measured after 24 hrs by MTT assay (Rvb = 100 +/- 6%)2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID1090894Phytotoxic activity against Agrostis stolonifera seeds assessed as inhibition of germination at 10 uM at 26 degC measured 12 days post-drug dose2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID673111Agonist activity at GPR120 expressed in HEK 293 cells assessed as beta-arrestin recruitment after 5 mins by BRET assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of a potent and selective GPR120 agonist.
AID1053273Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1090887Phytotoxic activity against Lactuca sativa (lettuce) seeds assessed as inhibition of germination at 1 uM at 26 degC measured 7 days post-drug dose2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID1519392Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1879357Antiinflammatory activity against LPS-stimulated C57BL/6 mouse microglial BV-2 cells assessed as reduction in cellular content of TNF-alpha level at 100 umol/L pretreated for 3 hrs followed by LPS stimulation and measured after 24 hrs by AlphaLISA assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Linotrins: Omega-3 oxylipins featuring an E,Z,E conjugated triene motif are present in the plant kingdom and alleviate inflammation in LPS-challenged microglial cells.
AID1678504Cytotoxicity against mouse Oli-neu cells assessed as cell viability at 1 uM measured after 24 hrs by MTT assay (Rvb = 100 +/- 6%)2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID1338209Inhibition of Staphylococcus aureus FabI using t-o-NAC-thioester as substrate by spectrophometric method2017European journal of medicinal chemistry, Jan-05, Volume: 125Antitubercular activity of 1,2,3-triazolyl fatty acid derivatives.
AID1519394Antibacterial activity against Staphylococcus epidermidis ATCC 12228 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID353555Inhibition of 5-alpha-reductase in rat liver microsome assessed as conversion of [14C] testosterone to [14C] dihydrotestosterone2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
AID347386Agonist activity at human GPR120-G-alpha-16 fusion protein expressed in Flp-in HEK293 cells assessed as effect on intracellular calcium concentration by FLIPR assay2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists.
AID1090873Antitermite activity against greater than third-instar stage of Coptotermes formosanus workers/1 soldier in compound-pretreated filter paper assessed as mortality at 0.5% at 26 degC after 6 days (Rvb = 2.5 +/-5%)2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID1090889Phytotoxic activity against Lactuca sativa (lettuce) seeds assessed as inhibition of germination at 100 uM at 26 degC measured 7 days post-drug dose2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID40631Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined at 2 x 10E-4 M1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1215093Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID627875Inhibition of histidine-tagged human DNA polymerase gamma using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID628060Inhibition of recombinant His-tagged human DNA polymerase lambda using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID627879Inhibition of C-terminal His6-tagged human DNA polymerase kappa (amino acids 1 to 560) using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1215091Activation of human PXR expressed in human HepG2 (DPX-2) cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1879359Antiinflammatory activity against LPS-stimulated C57BL/6 mouse microglial BV-2 cells assessed as reduction in cellular content of IL-1 beta level at 100 umol/L pretreated for 3 hrs followed by LPS stimulation and measured after 24 hrs by AlphaLISA assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Linotrins: Omega-3 oxylipins featuring an E,Z,E conjugated triene motif are present in the plant kingdom and alleviate inflammation in LPS-challenged microglial cells.
AID658576Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as modulation of isoniazid-mediated antibacterial activity measuring ratio of isoniazid MIC to isoniazid and compound MIC at 4 mg/L after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID402800Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with tissue factor for 90 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID1090891Phytotoxic activity against Agrostis stolonifera seeds assessed as inhibition of germination at 1 uM at 26 degC measured 12 days post-drug dose2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID402798Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with factor 7a for 90 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID627880Inhibition of recombinant His-tagged human DNA polymerase lambda using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1090888Phytotoxic activity against Lactuca sativa (lettuce) seeds assessed as inhibition of germination at 1000 uM at 26 degC measured 7 days post-drug dose2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID1053269Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1879358Antiinflammatory activity against LPS-stimulated C57BL/6 mouse microglial BV-2 cells assessed as reduction in cellular content of IL-6 level at 100 umol/L pretreated for 3 hrs followed by LPS stimulation and measured after 24 hrs by AlphaLISA assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Linotrins: Omega-3 oxylipins featuring an E,Z,E conjugated triene motif are present in the plant kingdom and alleviate inflammation in LPS-challenged microglial cells.
AID402797Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with factor 7a for 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID627976Cytotoxicity against human HCT116 cells by WST-1 assay2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1420967Agonist activity at recombinant human GPR40 expressed in HEK293 cells assessed as increase in intracellular calcium flux at 10 uM measured for 120 secs by calcium-5 dye based assay relative to 30 uM linolenic acid2018European journal of medicinal chemistry, Oct-05, Volume: 158Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
AID658575Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as modulation of EtBr-mediated antibacterial activity measuring ratio of EtBr MIC to EtBr and compound MIC at 4 mg/L after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID360927Inhibition of sheep COX2-mediated prostaglandin biosynthesis using [1-14C]arachidonic acid2001Journal of natural products, Jun, Volume: 64, Issue:6
Cox-2 inhibitory effects of naturally occurring and modified fatty acids.
AID1090874Antitermite activity against greater than third-instar stage of Coptotermes formosanus workers/1 soldier in compound-pretreated filter paper assessed as mortality at 0.5% at 26 degC after 1 day (Rvb = 0%)2007Journal of agricultural and food chemistry, Dec-26, Volume: 55, Issue:26
Phytotoxic Eremophilanes from Ligularia macrophylla.
AID677050Binding affinity to PPARgamma2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1519399Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID402796Inhibition of amidolytic activity of human recombinant soluble tissue factor (Ala-TF 1 to 219)/human factor 7a1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID627874Inhibition of calf DNA polymerase alpha using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1678492Neurotoxicity in rat primary Cerebellar granule neurone assessed as cell viability at 5 uM measured after 24 hrs by MTT assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1345809Human FFA1 receptor (Free fatty acid receptors)2003The Journal of biological chemistry, Mar-28, Volume: 278, Issue:13
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.
AID1345269Rat FFA4 receptor (Free fatty acid receptors)2008Naunyn-Schmiedeberg's archives of pharmacology, Jun, Volume: 377, Issue:4-6
Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta cells.
AID1345809Human FFA1 receptor (Free fatty acid receptors)2003Biochemical and biophysical research communications, Feb-07, Volume: 301, Issue:2
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.
AID1345809Human FFA1 receptor (Free fatty acid receptors)2003Nature, Mar-13, Volume: 422, Issue:6928
Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.
AID1345188Human FFA4 receptor (Free fatty acid receptors)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of a potent and selective GPR120 agonist.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,151)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990228 (7.24)18.7374
1990's451 (14.31)18.2507
2000's913 (28.97)29.6817
2010's1227 (38.94)24.3611
2020's332 (10.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.92 (24.57)
Research Supply Index8.18 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index141.33 (26.88)
Search Engine Supply Index2.07 (0.95)

This Compound (75.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials293 (8.95%)5.53%
Reviews281 (8.58%)6.00%
Case Studies7 (0.21%)4.05%
Observational7 (0.21%)0.25%
Other2,687 (82.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]